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Abstract  
 
Background: Cognitive impairment (CI) is estimated to be present in 25%-80% of heart failure (HF) 
patients, but its prevalence at diagnosis is unclear. To improve our understanding of cognition in HF, we 
determined the prevalence of CI among adults with incident HF in the REGARDS study. 
 
Methods: REGARDS is a longitudinal cohort study of adults >45 years of age recruited from 2003-2007. 
Incident HF was expert-adjudicated.  Cognitive function was assessed with the Six-Item-Screener. The 
prevalence of CI among those with incident HF was compared to the prevalence of CI among an age, sex, 
and race-matched cohort without HF.   
 
Results: The 436 participants with incident HF had a mean age of 70.3 years (SD 8.9), 47% were female, 
and 39% were black. Old age, black race, female gender, less education, and anticoagulation use were 
associated with CI.  The prevalence of CI among participants with incident HF (14.9% [11.7-18.6%]) was 
similar to the non-HF matched cohort (13.4% [11.6% – 15.4%], p<0.43).  
 
Conclusion: 14.9% of adults with incident HF had CI, suggesting that the majority of cognitive decline 
occurs after HF diagnosis.  Increased awareness of CI among newly diagnosed patients, and ways to 
mitigate it in the context of HF management, are warranted.  
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Abbreviations  
 
HF = heart failure      
CI = cognitive impairment          
SIS = Six-Item Screener 
CHD = coronary heart disease 
ECG = electrocardiogram 
eGFR = estimated glomerular filtration rate 
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Introduction 
Cognitive impairment (CI) is one of the most common comorbid conditions among adults with 
heart failure (HF) (1, 2) and is associated with poor quality of life (3) and self-care (4), and increased 
morbidity and mortality (5-7). While prior studies agree that CI is highly prevalent in HF, prevalence 
estimates vary widely, ranging from 25-80% (1, 7, 8).  Additionally, the underlying pathophysiology of CI 
and its trajectory in HF, remain uncertain (1, 7).  
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 Some uncertainty could be attributed to a lack of understanding of the prevalence of CI among 
adults with newly diagnosed disease. For example, if CI is prevalent at disease onset, then providers 
need to screen for cognitive deficits early and advise patients accordingly. If, however, adults with 
incident HF have similar cognitive profiles to adults without HF, then more attention ought to be 
focused on mitigating cognitive decline among those with existing HF.  Yet, few studies have 
investigated the prevalence of CI in incident HF. 
To fill this gap, we determined the prevalence and correlates of CI among adults with incident 
HF in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study, a national 
prospective cohort of 30,239 community-dwelling adults in the US aged >45 years.   
 
Methods 
REGARDS  
Details of the REGARDS study have been described previously (9).  Briefly, REGARDS is a cohort 
study that evaluates racial and geographic disparities in cardiovascular disease. Recruitment occurred 
from  2003 to 2007.  Blacks and residents of the Stroke Belt were oversampled by design (9). 
Participants completed a telephone interview followed by an in-home examination.  At six-month 
intervals, participants are asked about hospitalizations and health status.  The study was approved by 
the institutional review boards of all participating institutions. All participants provided written informed 
consent. 
 
Study Population 
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Adults with incident HF who underwent a cognitive assessment more than 1 month but less 
than 18 months prior to their incident HF diagnosis were included. One month was selected as a cutoff 
because individuals may experience cognitive changes as HF worsens.   
 
Incident Heart Failure 
 
 An incident HF diagnosis was defined as the participant’s first hospitalization for HF without a 
prior history of HF.  We included hospitalizations from 2004 to 2016. HF hospitalizations were 
adjudicated by two experts and disagreements were resolved by committee with κ>0.80 (10). Since 
hospitalizations for cardiac events can affect cognition, participants with hospitalizations for other 
cardiac etiologies known to REGARDS prior to their incident HF hospitalization, were excluded. 
 
Cognition  
REGARDS participants undergo global cognitive function assessments annually with the Six-Item 
Screener (SIS), a validated measure that assesses 3-item recall and orientation to year, month, and day 
of the week.(11)  The SIS, which can be administered easily by telephone, has a sensitivity of 74.2% to 
84.0% and specificity of 80.2% to 85.3% in community and clinical samples for a diagnosis of cognitive 
impairment.(11)  Scores for the SIS range from 0-6 and each correctly answered question receives 1 
point.(12-15)  Similar to other studies, scores were dichotomized; scores of 5 and 6 were normal, whilst 
scores of 4 and less connoted CI.   
Participant Characteristics 
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Demographic data included age, sex, race, education, annual household income, and region of 
residence.  Clinical data included history of coronary heart disease (CHD) by self-report or 
electrocardiogram (ECG); diabetes, defined as fasting blood glucose ≥126 mL/dL,  non-fasting glucose 
>200 mL/dL, oral hypoglycemic, or insulin use; history of hypertension, defined as systolic blood 
pressure >140, diastolic blood pressure of >90, or medication use for hypertension; history of atrial 
fibrillation by self-report or by ECG; history of self-reported stroke; chronic kidney disease, defined as 
eGFR <60ml/min/1.732 ; body mass index; cigarette smoking; high‐density lipoprotein and total 
cholesterol.  Left ventricular ejection fraction was abstracted from the most recent echocardiogram. 
Depressive symptoms were assessed with the 4-item Center for Epidemiological Studies-Depression 
scale (16).  Medication use at baseline was ascertained.  
 
Healthy Comparison Population  
To contextualize our findings, we compared the prevalence of CI among adults with incident HF 
to that of an age, sex, and race-matched group of participants without HF. We matched participants (3:1 
ratio) who did not have an adjudicated HF hospitalization or another adjudicated cardiovascular event in 
REGARDS, and were similar in age (+/- 5 years), gender, race, and year of SIS, to each HF participant. 
Matching was performed with SAS macro gmatch which uses a “greedy” algorithm approach (17) (18).   
 
Statistical Analysis  
The prevalence of CI was determined among participants with incident HF and among the 
matched control group.  First, we examined differences in participant characteristics by CI.  Next, we 
performed multivariable logistic regression to examine associations between participant characteristics 
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and CI among those with incident HF. Multiple imputation with chained equations was used to account 
for missing data.  Analyses were conducted with STATA and statistical significance for all analyses was 
set as P < .05 (2-sided).  
 
Results 
 
CI in Incident HF 
 
 539 participants were hospitalized for incident HF (Supplemental Figure 1). Among them, 103 
lacked a SIS, leaving 436 in the final analytic cohort. Of note, there were no clinical differences between 
this cohort and the 103 who were excluded.   
Overall participants had a mean age of 70 (SD+8.9) years, 53.0% were male, 60.6% were white, 
the majority (82.1%) had > high school education, 77.8% had hypertension, 38.5% had diabetes, and 
31.9% had CHD (Table 1).  The prevalence of CI was 14.9% [95% CI: 11.7, 18.6%]. Participants with CI 
were older, male, and less educated than those without CI.  The majority of clinical characteristics did 
not differ by cognition.  
Among participants with incident HF, older age (1.04 [1.01, 1.08]), black race (1.88 [1.08, 3.28]), 
less education (1.89 [1.02, 3.51]), higher SBP (1.01 [1.00,1.02]), and anticoagulant use (3.01 [1.05,8.63]) 
were associated with higher odds of CI, whereas female sex (0.54 [0.31,0.94]) was associated with lower 
odds of CI, in an age-adjusted model (Table 2). In a fully adjusted model, age, gender, race, and 
anticoagulant use remained independently associated with CI. 
 
CI in Healthy Comparison Population 
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 1,307 participants comprised the healthy comparison population (Supplemental Figure 2).  
Participants with CI were older, male, black, and had less education and income than those without CI 
(Table 3). Again, hypertension (62.5%), CHD (20%), and Diabetes (20%) were prevalent. The overall 
prevalence of CI was 13.4% (95% CI: 11.6 – 15.4%), which did not differ from the incident HF cohort 
(p<0.43).   
 
Discussion  
 
 Overall, 14.9% of adults with incident HF had CI, indicating that healthcare providers should 
consider assessing cognition at the time HF diagnosis.   Since the prevalence of CI among adults with 
existing HF ranges between 25% and 80% (1, 19), our results, alongside 2 recent studies in the 
Cardiovascular Health Study(20, 21), suggest that CI may develop during the course of the disease itself, 
rather than at the outset or due to CHD risk factors alone (7, 22).   
 Prior studies have attributed cognitive decline in HF to disease duration and severity (23).  
Underlying mechanisms include cerebral hypo-perfusion, multiple cardiogenic emboli, and impaired 
microcirculation (1, 23-26).  Thus, among newly diagnosed HF patients, in addition to mitigating CHD risk 
factors, increased attention to interventions and medications which have the ability to affect these 
underlying processes may be most important to preserving cognitive function (7).    
Similar to other studies (27, 28), we found older age, black race, and less education to be 
associated with CI, indicating that certain patient subgroups may require targeting at diagnosis.  
Interestingly, many clinical characteristics known to be associated with CI in HF were not associated with 
CI in incident HF.  This may be due to our relatively small sample size and because the severity of some 
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factors may be less at HF onset.  In addition, index event bias may support these unanticipated 
observations (29).  
The prevalence of CI (13.4%) among a matched sub-cohort without HF did not differ significantly 
from the incident HF cohort, and was comparable to other populations of similar age and comorbidity 
status (30, 31).  This finding supports our main finding, but also speaks to the accumulating evidence 
which has shown CHD and CHD risk factors to be associated with the development of CI (15, 30-33).  
Strengths of our study include a geographically and racially diverse cohort, expert-adjudicated 
outcomes, and the measurement of cognition prior to an incident HF hospitalization, which minimizes 
the bias of clinical deterioration on cognition.   Limitations include that cognition was assessed with 1 
screener; although the SIS is brief, reliable, and validated against the MMSE (11), it is less sensitive for 
the detection of mild CI (34-36). Additionally, we did not study other cognitive domains which are 
relevant to self-care (34, 36).  Finally, incident HF diagnoses made in the ambulatory setting were not 
included, which limits the generalizability.(37)  
 
Conclusion 
 14.9% of adults hospitalized for incident HF had CI in a range consistent with varying levels of 
CHD risk in a similarly aged group of adults. The majority of the cognitive decline previously reported in 
HF may occur over the course of the disease rather than prior to presentation.  Increased awareness of 
the prevalence of CI among newly diagnosed HF patients, and ways to mitigate cognitive decline in the 
context of HF management, are warranted. 
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Table 1.  Baseline Characteristics of REGARDS participants with Incident Heart Failure by Cognitive 
Status 
 
Characteristic 
All Participants       
(n = 436) 
No Cognitive 
Impairment 
(n = 371) 
Cognitive 
Impairment 
(n=65) 
P-value 
Prevalence of Cognitive Impairment: 14.9% (95% CI: 11.7-18.6%) 
Demographic Characteristics 
Age, years(SD) 70.31 (8.98) 69.81 (8.94) 73.14 (8.73) 0.006* 
Gender, n (%) 
   
0.02* 
Male 231 (53.0%) 188 (50.7%) 43 (66.2%) 
 
Female 205 (47.0%) 183 (49.3%) 22 (33.8%) 
 
Race, n (%) 
   
0.14 
White 264 (60.6%) 230 (62.0%) 34 (52.3%) 
 
Black 172 (39.4%) 141 (38.0%) 31 (47.7%) 
 
Education, n (%) 
   
0.03* 
Less than high school 78 (17.9%) 60 (16.2%) 18 (27.7%) 
 
High school or higher 358 (82.1%) 311 (83.8%) 47 (72.3%) 
 
Income, n (%)  
   
0.87 
< $35K 234 (53.7%) 202 (54.4%) 32 (49.2%) 
 
 $35K 147 (33.7%) 126 (34.0%) 21 (32.3%)  
Region of Residence, n (%) 
   
0.79 
Belt 166 (38.1%) 139 (37.5%) 27 (41.5%) 
 
Buckle 94 (21.6%) 80 (21.6%) 14 (21.5%) 
 
Non-belt 176 (40.4%) 152 (41.0%) 24 (36.9%) 
 
Clinical Characteristics 
Heart Failure Type, n (%) 
   
0.76 
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HFrEF <50 198 (45.4%) 168 (45.3%) 30 (46.2%) 
 
HfpEF 50 178 (40.8%) 153 (41.2%) 25 (38.5%) 
 
Coronary Heart Disease, n (%)  139 (31.9%) 116 (31.3%) 23 (35.4%) 0.51 
Diabetes Mellitus, n (%) 168 (38.5%) 142 (38.3%) 26 (40.0%) 0.93 
Hypertension, n (%) 339 (77.8%) 288 (77.6%) 51 (78.5%) 0.91 
Stroke, n (%) 50 (11.5%) 41 (11.1%) 9 (13.8%) 0.52 
Atrial Fibrillation, n (%) 18 (4.1%) 15 (4.0%) 3 (4.6%) 0.82 
Chronic Kidney Disease, n (%) 113 (25.9%) 93 (25.1%) 20 (30.8%) 0.34 
Depressive symptoms, n (%) 60 (13.8%) 55 (14.8%) 5 (7.7%) 0.12 
General Health, n (%)  
   
0.68 
Poor 23 (5.3%) 20 (5.4%) 3 (4.6%) 
 
Fair 112 (25.7%) 98 (26.4%) 14 (21.5%) 
 
Good 161 (36.9%) 136 (36.7%) 25 (38.5%) 
 
Very good 102 (23.4%) 83 (22.4%) 19 (29.2%) 
 
Excellent  38 (8.7%) 34 (9.2%) 4 (6.2%) 
 
Body Mass Index (kg/m2), 
mean (SD) 
30.2 (6.6) 30.3 (6.7) 29.8 (6.5) 0.56 
Waist circumference (cm), 
mean (SD) 
102.2 (16.7) 101.91 (16.11) 103.87 (19.8) 0.39 
Systolic blood pressure 
(mmHg), mean, (SD) 
134.4 (19.0) 133.9 (18.8) 137.4 (19.5) 0.17 
Total Cholesterol (mg/dL), 
mean (SD) 
184.8 (41.9) 186.0 (41.9) 177.9 (42.0) 0.15 
HDL Cholesterol (mg/dL), mean 
(SD) 
47.1 (14.2) 47.4 (14.4) 45.8 (13.0) 0.43 
Health Behaviors 
Smoking History, n (%) 
   
0.88 
Never 182 (41.7%) 157 (42.3%) 25 (38.5%) 
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Current 66 (15.1%) 56 (15.1%) 10 (15.4%) 
 
Former 186 (42.7%) 157 (42.3%) 29 (44.6%) 
 
Alcohol Use, n (%) 
   
0.84 
Never 143 (32.8%) 122 (32.9%) 21 (32.3%) 
 
Current 191 (43.8%) 164 (44.2%) 27 (41.5%) 
 
Past 102 (23.4%) 85 (22.9%) 17 (26.2%) 
 
Medication Use 
Anti-platelet**, n (%) 239 (54.8%) 204 (55.0%) 35 (53.8%) 0.86 
Anticoagulation, n (%) 17 (3.9%) 11 (3.0%) 6 (9.2%) 0.02* 
Statin, n (%)  170 (39.0%) 147 (39.6%) 23 (35.4%) 0.52 
Anti-Hypertensive, n (%) 298 (68.3%) 255 (68.7%) 43 (66.2%) 0.92 
Insulin, n (%) 52 (11.9%) 45 (12.1%) 7 (10.8%) 0.75 
*Significant at p<0.05; missing values included income (n=55 ), Heart failure type (n=60), coronary heart disease 
(n=7), diabetes (n=11), hypertension (n= 11), stroke(n=1), atrial fibrillation (n=3), Chronic kidney disease (n=15), 
depressive symptoms (n=2), waist circumference (n=3), systolic blood pressure (n=1), total cholesterol (n=15), HLD 
(n=17), smoking status (n=2), aspirin (n=1), anti-hypertensives (10) 
**Includes aspirin and clopidogrel 
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Table 2.  Association Between Baseline Characteristics of REGARDS Participants with Incident Heart 
Failure and the Odds of Cognitive Impairment 
 
Characteristic 
Model 1 (Age-adjusted) Model 2 
OR (95% CI) OR (95% CI) 
Age 1.04 [1.01,1.08] 1.05 [1.02,1.09] 
Female 0.54 [0.31,0.94] 0.48 [0.27,0.85] 
Black 1.88 [1.08,3.28] 1.83 [1.01,3.32] 
Less than high school education 1.89 [1.02,3.51] 1.79 [0.92,3.46] 
Region of residence   
Belt ref ref 
Buckle 0.89 [0.44,1.81] 0.85 [0.41,1.76] 
Non-belt 0.72 [0.39,1.32] 0.62 [0.33,1.16] 
Systolic blood pressure 1.01 [1.00,1.02] 1.01 [0.99,1.02] 
Anticoagulation use 3.01 [1.05,8.63] 3.00 [1.00,8.99] 
 *p<0.05; Model 1: Age-adjusted; Model 2: Fully adjusted 
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Table 3. Baseline Characteristics of a Matched Cohort of REGARDS Participants Without Heart Failure 
 
Characteristic 
All Participants      
(n =1307) 
Cognitively 
Intact  
(n = 1132) 
Cognitively 
Impaired 
(n=175) 
P-value 
Prevalence of Cognitive Impairment: 13.4% (95% CI: 11.6 – 15.4%) 
Demographic Characteristics 
Age, years(SD) 70.28 (8.94) 69.56 (8.90) 74.99 (7.67) <0.001* 
Gender, n (%) 
   
<0.001* 
Male 692 (52.9%) 575 (50.8%) 117 (66.9%) 
 
Female 615 (47.1%) 557 (49.2%) 58 (33.1%) 
 
Race, n (%) 
   
<0.001* 
White 791 (60.5%) 707 (62.5%) 84 (48.0%) 
 
Black 516 (39.5%) 425 (37.5%) 91 (52.0%) 
 
Education, n (%) 
   
<0.001* 
< High school 200 (15.3%) 145 (12.8%) 55 (31.4%) 
 
 High school 1106 (84.6%) 987 (87.2%) 119 (68.0%) 
 
Income, n (%)  
   
<0.001* 
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< $ 35K 619 (47.4%) 520 (45.9%) 99 (56.6%) 
 
 $35k 482 (36.9%) 439 (38.8%) 43 (24.6%) 
 
Region of Residence, n(%) 
   
0.03* 
Belt 436 (33.4%) 372 (32.9%) 64 (36.6%) 
 
Buckle 303 (23.2%) 276 (24.4%) 27 (15.4%) 
 
Non-belt 568 (43.5%) 484 (42.8%) 84 (48.0%) 
 
Clinical Characteristics 
Heart Disease, n (%)  262 (20.0%) 212 (18.7%) 50 (28.6%) 0.002* 
Diabetes Mellitus, n (%) 261 (20.0%) 219 (19.3%) 42 (24.0%) 0.14 
Hypertension, n (%) 817 (62.5%) 705 (62.3%) 112 (64.0%) 0.68 
Stroke, n (%) 92 (7.0%) 75 (6.6%) 17 (9.7%) 0.14 
Atrial Fibrillation, n (%) 50 (3.8%) 42 (3.7%) 8 (4.6%) 0.59 
Chronic Kidney Disease,  
n (%) 
200 (15.3%) 154 (13.6%) 46 (26.3%) <0.001* 
Depressive symptoms,  
n (%) 
139 (10.6%) 113 (10.0%) 26 (14.9%) 0.05* 
General Health, n (%)  
    
Poor 34 (2.6%) 29 (2.6%) 5 (2.9%) 0.35 
Fair 192 (14.7%) 158 (14.0%) 34 (19.4%) 
 
Good 462 (35.3%) 404 (35.7%) 58 (33.1%) 
 
Very good 417 (31.9%) 366 (32.3%) 51 (29.1%) 
 
Excellent  197 (15.1%) 174 (15.4%) 23 (13.1%) 
 
Body Mass Index (kg/m2), 
mean (SD) 
28.4 (5.4) 28.5 (5.4) 27.5 (4.9) 0.02* 
Waist circumference (cm), 
mean (SD) 
95.6 (13.9) 95.5 (14.2) 96.4 (12.7) 0.41 
Systolic blood pressure 129.7 (17.1) 129.4 (17.1) 131.9 (17.3) 0.06 
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(mmHg), mean, (SD) 
Total Cholesterol (mg/dL), 
mean (SD) 
189.9 (40.4) 190.7 (40.4) 185.2 (40.2) 0.11 
HDL Cholesterol (mg/dL), 
mean (SD) 
51.7 (16.7) 52.2 (16.7) 48.6 (16.4) 0.01* 
Health Behaviors 
Smoking History, n (%) 
   
0.26 
Never 568 (43.5%) 487 (43.0%) 81 (46.3%) 
 
Current 161 (12.3%) 146 (12.9%) 15 (8.6%) 
 
Former 566 (43.3%) 489 (43.2%) 77 (44.0%) 
 
Alcohol Use, n (%) 
   
0.02* 
Never 405 (31.0%) 338 (29.9%) 67 (38.3%) 
 
Current 639 (48.9%) 570 (50.4%) 69 (39.4%) 
 
Former 263 (20.1%) 224 (19.8%) 39 (22.3%) 
 
Medication Use 
Anti-platelet**, n (%) 615 (47.1%) 537 (47.4%) 78 (44.6%) 0.48 
Anticoagulation, n (%) 41 (3.1%) 34 (3.0%) 7 (4.0%) 0.48 
Statin, n (%)  429 (32.8%) 367 (32.4%) 62 (35.4%) 0.43 
Anti-Hypertensive, N (%) 709 (54.2%) 616 (54.4%) 93 (53.1%) 0.82 
Insulin, n (%) 33 (2.5%) 29 (2.6%) 4 (2.3%) 0.83 
*significant at p<0.05; missing values included education(n=1), income (n=206 ), coronary heart disease (n= 26), 
diabetes (n=44), hypertension (n=2 ), stroke(n=3), atrial fibrillation (n=18), Chronic kidney disease (n=52), 
depressive symptoms (n=14), waist circumference ( n=6), systolic blood pressure (n= 2 ), total cholesterol (n=52 ), 
HDL (n=58),smoking status (n=12 ), aspirin (n=2 ), anti-hypertensives (n=37) 
**includes aspirin and clopidogrel 
 
 
